Regeneron Pharmaceuticals Inc

REGN-Q

NASDAQ:REGN

583.14
16.60 (2.77%)
Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988.
More at Wikipedia

Analysis and Opinions about REGN-Q

Signal
Opinion
Expert
BUY
BUY
September 30, 2020
Just announced that their new drug cocktail can treat Covid immediately upon testing positive. The stock actually went down today, but he's been recommending this for a while.
Show full opinionHide full opinion
Just announced that their new drug cocktail can treat Covid immediately upon testing positive. The stock actually went down today, but he's been recommending this for a while.
TOP PICK
TOP PICK
July 17, 2019
A higher-risk/return play. This biotech has several core products generating good free cash flow. They’re partnering with Sanofi on Dupixent to treatment severe atopic dermatitis and potentially severe asthma. They also have another drug to treat specific eye diseases. REGN boasts various late-stage drug trials. Regeneron is a new Top Pick for us, driven by the valuation having compressed significantly on concerns over U.S. Medicare Part B drug pricing policy proposals. We believe these are more than reflected in the current price.Their dermatitis drug is getting traction. This stock has been beat up for the wrong reasons. This (Analysts’ price target is $389.38)
Show full opinionHide full opinion
A higher-risk/return play. This biotech has several core products generating good free cash flow. They’re partnering with Sanofi on Dupixent to treatment severe atopic dermatitis and potentially severe asthma. They also have another drug to treat specific eye diseases. REGN boasts various late-stage drug trials. Regeneron is a new Top Pick for us, driven by the valuation having compressed significantly on concerns over U.S. Medicare Part B drug pricing policy proposals. We believe these are more than reflected in the current price.Their dermatitis drug is getting traction. This stock has been beat up for the wrong reasons. This (Analysts’ price target is $389.38)
BUY
BUY
May 3, 2019
Diversity is key. Large biotech has been beat up. Speculation that Novartis is a competitor, but it's at early stages for them. REGN does have a drug for a niche market. Correction is in part because of Novartis speculation plus medicare reimbursement. Current multiple around 13x, you can buy it, but buy it in a basket.
Show full opinionHide full opinion
Diversity is key. Large biotech has been beat up. Speculation that Novartis is a competitor, but it's at early stages for them. REGN does have a drug for a niche market. Correction is in part because of Novartis speculation plus medicare reimbursement. Current multiple around 13x, you can buy it, but buy it in a basket.
PAST TOP PICK
PAST TOP PICK
May 23, 2018

(Past Top Pick on August 8, 2017, Down 40%) Sold his at a stop loss before things got worse. You must be ruthless in selling your losers or you'll suffer even more downside.

Show full opinionHide full opinion

(Past Top Pick on August 8, 2017, Down 40%) Sold his at a stop loss before things got worse. You must be ruthless in selling your losers or you'll suffer even more downside.

TOP PICK
TOP PICK
June 20, 2017

He likes biotech as a space, and it has recently re-accelerated. This company has a number of key drugs. Their major drug is Eylea for macular degeneration, a multi-, multi-billion-dollar drug. However, they have a newer drug, which is aimed at the allergy market, which could potentially be a $10 billion drug. This company will double its earnings in the next 3 years and is not dependent on one product. (Analysts’ price target is $438.)

Show full opinionHide full opinion

He likes biotech as a space, and it has recently re-accelerated. This company has a number of key drugs. Their major drug is Eylea for macular degeneration, a multi-, multi-billion-dollar drug. However, they have a newer drug, which is aimed at the allergy market, which could potentially be a $10 billion drug. This company will double its earnings in the next 3 years and is not dependent on one product. (Analysts’ price target is $438.)

HOLD
HOLD
June 1, 2016

Loves the biotech sector right now. If he had to invest money in one sector right now, it would be Biotechs. He likes this company. They are positioned very well.

Show full opinionHide full opinion

Loves the biotech sector right now. If he had to invest money in one sector right now, it would be Biotechs. He likes this company. They are positioned very well.

Showing 1 to 6 of 6 entries
  • «
  • 1
  • »

Regeneron Pharmaceuticals Inc(REGN-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Regeneron Pharmaceuticals Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Regeneron Pharmaceuticals Inc(REGN-Q) Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc stock symbol?

Regeneron Pharmaceuticals Inc is a American stock, trading under the symbol REGN-Q on the NASDAQ (REGN). It is usually referred to as NASDAQ:REGN or REGN-Q

Is Regeneron Pharmaceuticals Inc a buy or a sell?

In the last year, 1 stock analyst published opinions about REGN-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Regeneron Pharmaceuticals Inc.

Is Regeneron Pharmaceuticals Inc a good investment or a top pick?

Regeneron Pharmaceuticals Inc was recommended as a Top Pick by Jim Cramer - Mad Money on 2020-09-30. Read the latest stock experts ratings for Regeneron Pharmaceuticals Inc.

Why is Regeneron Pharmaceuticals Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Regeneron Pharmaceuticals Inc worth watching?

1 stock analyst on Stockchase covered Regeneron Pharmaceuticals Inc In the last year. It is a trending stock that is worth watching.

What is Regeneron Pharmaceuticals Inc stock price?

On 2020-10-19, Regeneron Pharmaceuticals Inc (REGN-Q) stock closed at a price of $583.14.